This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Benfluorex | |
|---|---|
| Name | Benfluorex |
| Other names | (none linked) |
| Tradename | (none linked) |
| Legal status | Withdrawn |
| Routes of administration | Oral |
| Cas number | 37102-58-4 |
| Atc prefix | A10 |
| Atc suffix | BH04 |
| Chemspider id | 21106491 |
Benfluorex Benfluorex was an appetite suppressant and antihyperglycemic agent developed and marketed primarily in Europe and parts of Asia. Initially promoted for Type 2 diabetes mellitus adjunct therapy and weight management, it became the center of major safety controversies involving cardiac valvulopathy, regulatory withdrawals by bodies such as the European Medicines Agency and national agencies, and extensive litigation affecting pharmaceutical manufacturers and distributors.
Benfluorex emerged in the late 20th century amid renewed interest in anorectic agents and antidiabetic adjuncts, marketed in countries including France, Spain, and Brazil. Its commercial history intertwined with corporate entities and regulatory authorities like the Laboratoires Servier corporate group, national drug agencies, and supranational regulators including the European Commission. Clinical adoption overlapped with contemporaneous use of agents such as fenfluramine, dexfenfluramine, and metformin for overlapping indications.
Benfluorex is a substituted phenethylamine derivative structurally related to fenfluramine and amfetamine-class compounds, characterized by a fluorine-containing aromatic moiety and an N-substituted aminoethyl side chain. Its molecular formula and stereochemistry impart lipophilicity influencing oral bioavailability and tissue distribution, including cardiac tissue and pulmonary vasculature. In vitro assays and animal models performed in research centers affiliated with institutions such as INSERM, CNRS, and various university departments demonstrated affinity for monoaminergic systems, including interactions with serotonin transport and receptor pathways implicated in valvular homeostasis. Metabolic studies carried out in laboratories connected to pharmaceutical firms and academic centres showed biotransformation to active metabolites resembling those of fenfluramine.
Benfluorex was prescribed as an adjunct to dietary and lifestyle interventions in patients with Type 2 diabetes mellitus and overweight individuals, often alongside agents like sulfonylureas or insulin in clinical practice contexts overseen by specialist prescribers in endocrinology clinics and primary care networks. Proposed mechanisms invoked anorectic effects mediated by central nervous system monoamine modulation, and peripheral modulation of glycemic control proposed by proponents and some clinical investigators affiliated with university hospitals and specialist societies. Pharmacodynamic studies referenced pathways associated with serotonin 5-HT2B receptors and platelet-derived growth factor signaling, mechanisms also explored in pharmacology departments at institutions such as Harvard Medical School, INSERM, and University of Paris laboratories.
Post-marketing surveillance, case series in tertiary hospitals, and pharmacoepidemiological studies from agencies like the Agence nationale de sécurité du médicament et des produits de santé and academic collaborators reported an association between benfluorex exposure and restrictive valvular heart disease similar to that previously observed with fenfluramine and dexfenfluramine. Reports documented involvement of mitral and aortic valves leading to regurgitation and heart failure diagnosed in cardiology units in hospitals affiliated with Assistance Publique–Hôpitaux de Paris, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, and other centers. Pulmonary arterial hypertension cases were evaluated by specialist groups including investigators linked to the World Health Organization and national registries. Pathophysiological investigations by researchers at Johns Hopkins University, Imperial College London, and Karolinska Institutet implicated 5-HT2B receptor agonism, fibrotic remodeling, and serotonergic metabolite-induced valvulopathy.
In response to accumulating evidence from pharmacovigilance databases, cohort studies, and meta-analyses, regulators including the European Medicines Agency, the French National Agency for Medicines and Health Products Safety, and the Brazilian Health Regulatory Agency ordered suspension and withdrawal of benfluorex-containing products. Litigation and public inquiries involved governmental bodies such as the French Ministry of Health and parliamentary commissions, as well as regulatory reviews by the European Commission and national courts. Withdrawal actions mirrored prior regulatory steps taken for congeners such as fenfluramine in jurisdictions including the United States Food and Drug Administration and prompted revisions to pharmacovigilance practices internationally.
Legal proceedings stemming from alleged harms attributed to benfluorex encompassed civil suits, criminal investigations, and class-action style claims in jurisdictions including France, Brazil, and other countries where the drug was marketed. Plaintiff representatives, expert witnesses from university hospitals, and national bar associations contested matters involving corporate accountability of manufacturers and marketing affiliates, leading to judgments, fines, and settlements. High-profile trials engaged public figures, regulatory officials, and medical experts from institutions such as Université Paris Descartes and medico-legal consultants, with outcomes influencing corporate governance and pharmaceutical compliance standards in Europe and Latin America.
Epidemiological assessments using data from hospital episode statistics, national health insurance databases like the French National Health Insurance Fund, and cohort studies in academic networks estimated excess cases of valvular disease and heart failure attributable to benfluorex exposure. Public health responses involved screening programs in cardiology clinics, risk communication by ministries such as the French Ministry of Health and Brazilian Ministry of Health, and research funded by public agencies and foundations. The benfluorex episode contributed to reforms in post-marketing surveillance, pharmacovigilance legislation debated in national parliaments, and academic discourse at conferences hosted by organizations including the European Society of Cardiology and the International Society of Pharmacovigilance.
Category:Withdrawn drugs